BridgeBio Pharma (BBIO) Stock: -10.2% Over 30 Days but +12.6% Quarterly – What Stands Out
Key Takeaways
- BridgeBio Pharma shares declined roughly 10.2% over the trailing 30 days, falling from a closing price of $84.48 on August 7, 2026, to about $75.89.
- Despite the recent pullback, BBIO remains up approximately 12.6% over the trailing quarter, reflecting a broader, multi-month uptrend.
- The short-term decline followed profit-taking after a strong run, an oversubscribed secondary offering by selling stockholder KKR, and fading momentum.
- Second-quarter 2026 revenue rose 120% year over year to $243.7 million, driven by the ATTR-CM therapy Attruby.
- Three late-stage programs are under U.S. FDA review, with BBP-418 carrying a PDUFA target action date of November 27, 2026.
BridgeBio Pharma (BBIO) Company Overview and Market Position
BridgeBio Pharma, Inc. is a commercial-stage biopharmaceutical company headquartered in Palo Alto, California, focused on developing medicines for genetic diseases and cancers. Founded in 2015, the company operates a hub-and-spoke model that spans target identification, preclinical research, clinical development, and commercialization. Its flagship product is Attruby (acoramidis), an oral transthyretin stabilizer approved for transthyretin amyloid cardiomyopathy (ATTR-CM), a progressive heart condition. The therapy is marketed as Beyonttra in the European Union and Japan. BridgeBio competes in the ATTR-CM market against Pfizer's Vyndaqel/Vyndamax franchise and Alnylam's Amvuttra. Beyond Attruby, the pipeline includes BBP-418 for limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9), encaleret for autosomal dominant hypocalcemia type 1 (ADH1), and infigratinib for achondroplasia. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
BridgeBio Pharma (BBIO) Stock Price Performance: Last 30 Days vs. Quarter
Over the trailing 30 days, BBIO moved from a closing price of $84.48 on August 7, 2026, to approximately $75.89, a decline of about 10.2%. The stock reached an intraday 52-week high around $93 in July before retracing through August and into early September. The quarterly picture is different. About three months earlier, on June 8, 2026, the stock closed at $67.37. Against that level, the current price of roughly $75.89 represents a gain of approximately 12.6%. In short, the recent 30-day decline is a pullback within a still-positive multi-month trend.
What Drove BBIO Stock Price in the Last 30 Days
The 30-day decline reflects a combination of technical, supply, and sentiment factors rather than a single negative clinical event. After a sharp multi-month advance, shares became vulnerable to profit-taking, and the stock recorded a multi-session losing streak through late August and early September. A key supply-side catalyst came on August 14, 2026, when BridgeBio announced the pricing of an oversubscribed secondary offering of 5 million shares by selling stockholder KKR Genetic Disorder L.P. The company received no proceeds from the sale, but the increased float created near-term overhang on the shares. Second-quarter results, reported in early August, were mixed. Total revenue beat expectations at $243.7 million, and Attruby net product revenue reached $222.4 million, more than triple the prior-year figure. However, the company posted a wider-than-expected loss of $0.78 per share as research, development, and commercialization spending rose. This combination of strong top-line growth with persistent operating losses contributed to investor reassessment of near-term valuation.
What Drove BBIO Stock Performance Over the Last Quarter
The broader quarterly gain was driven by sustained commercial execution. Attruby continued to gain first-line market share, and management described it as the fastest-growing brand in the ATTR-CM category. On August 30, 2026, BridgeBio presented new Phase 3 ATTRibute-CM data at the European Society of Cardiology Congress showing durable improvements in cardiac function among acoramidis-treated patients, reinforcing the product's clinical differentiation. The quarter also featured supportive analyst activity. Cantor Fitzgerald reiterated a positive rating with a $110 price target, Mizuho raised its target to $110 from $96, and Wells Fargo raised its target to $102 from $98. A $1 billion preferred equity financing led by Sixth Street closed on July 1, lifting the company's pro forma cash balance to roughly $1.7 billion and supporting plans for three potential launches over the following year.
BBIO Stock Forecast Drivers: What Investors Should Watch Next
Investors monitoring BridgeBio should focus on several upcoming milestones. The FDA decision on BBP-418 for LGMD2I is expected by November 27, 2026, and the agency's action on encaleret for ADH1 carries a May 8, 2027 target date. The company has also submitted a new drug application for infigratinib in achondroplasia, with potential approval in mid-2027. Attruby's commercial trajectory remains central, particularly first-line share gains against Pfizer's tafamidis and Alnylam's Amvuttra. Continued revenue growth, progress toward operating break-even, and updates on the chronic hypoparathyroidism Phase 3 program will also shape sentiment. As with any development-stage biopharmaceutical company, regulatory outcomes, clinical data, and capital allocation decisions remain key sources of risk. From what I see, this is important because it highlights the balance between near-term commercial traction and longer-term pipeline catalysts.
Integrating AI Tools Into My Analysis
In my own research on names like BBIO, I often turn to Tickeron’s Trending AI Robots for a curated view of AI-powered trading strategies. The platform highlights top-performing bots across thousands of tickers, with details on strategy, holding periods, and performance metrics that help compare approaches suited to different risk levels and styles. Exploring these options has helped me identify data-driven signals and refine how I evaluate opportunities without replacing my fundamental work.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
BBIO's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for BBIO turned positive on October 01, 2026. Looking at past instances where BBIO's MACD turned positive, the stock continued to rise in 42 of 46 cases over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where BBIO's RSI Oscillator exited the oversold zone, 15 of 17 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 88%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 55 of 64 cases where BBIO's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 86%.
Following a +2.20% 3-day Advance, the price is estimated to grow further. Considering data from situations where BBIO advanced for three days, in 249 of 302 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
BBIO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 08, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BBIO as a result. In 76 of 97 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 78%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BBIO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
The Aroon Indicator for BBIO entered a downward trend on October 09, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 2 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-16.392) is normal, around the industry mean (26.780). P/E Ratio (0.000) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (18.587) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating steady price growth. BBIO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 79 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BBIO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company which engages in developing transformative medicines to treat patients who suffer from mendelian diseases.
Industry Biotechnology
Advertisement